Navigation Links
DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results
Date:8/11/2009

WILMINGTON, Mass., Aug. 11 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.((R)) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan((R)) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the second quarter ended June 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090810/DC59366LOGO)

Financial highlights for the second quarter and first half of the year include:

  • Domestic PDT revenues totaled $6.1 million for the second quarter of 2009, representing a $1.2 million, or 24%, improvement as compared to the second quarter of 2008. First half 2009 domestic PDT revenues totaled $12.4 million, representing a $2.3 million, or 22%, improvement year over year.
  • Domestic Kerastick((R)) revenues totaled $5.6 million for the second quarter of 2009, representing a $1.0 million, or 23%, improvement as compared to the second quarter of 2008. First half 2009 domestic Kerastick((R) )revenues totaled $11.3 million, representing a $2.0 million, or 21%, improvement year over year.
  • Domestic BLU-U((R)) revenues totaled $0.5 million for the second quarter of 2009, representing a $0.1 million, or 38%, improvement as compared to the second quarter of 2008. First half 2009 domestic BLU-U((R)) revenues totaled $1.1 million, representing a $0.3 million, or 36%, improvement year over year.
  • Kerastick((R)) gross margins for the second quarter of 2009 reached a record high of 85%.

Management Comments:

"While
'/>"/>

SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... Castle ... to the practice. Dr. Pedram Ghasri is a graduate of the University of California, ... and continued his studies at the University of California, Irvine Medical School. As a ...
(Date:8/31/2015)... IL (PRWEB) , ... August 31, 2015 , ... In ... studies, Etymotic Research, maker of the BEAN™ personal sound amplifier, is offering caregivers “7 ... sound amplifiers as a way of coping with a variety of home healthcare challenges, ...
(Date:8/31/2015)... ... 2015 , ... For 12 years, since 2004, the Mesothelioma Applied Research ... Awareness Day . On this day, and in the weeks leading up to it, ... helping the cause. , “One of the ways a person can be involved is ...
(Date:8/31/2015)... ... ... MeYou Health ®, a social well-being company and wholly owned subsidiary of Healthways, ... in-app step tracker. , Walkadoo is a pedometer-based walking program that provides ... every Walkadoo member 10,000 steps a day (as is typical for many walking programs), ...
(Date:8/31/2015)... ... August 31, 2015 , ... It’s a lot like coming home. Life-long Fox ... Geneva. During his first days on the job, he’s run into residents of the ... I like knowing that they’re living in such a wonderful place,” he said. GreenFields, ...
Breaking Medicine News(10 mins):Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 3Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Walkadoo™ Walking Program Now Includes In-app Step Tracker 2Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2
... is no stopping the Chinese. Not a single sphere in ... The next target in its crosshairs is the cooked ... it very glibly, "China is seeking to familiarize the U.S. ... poultry lobby is worried. It talks about such common practices ...
... of those who take herbal supplements, do not check scientific ... herbal medicines to ease specific ailments do so on the ... the credentials of purported claims or seek evidence based results. ... of Iowa viewed extensive data from a 2002 national health ...
... goal for inflation of an angioplasty balloon in a ... is so revered its been codified in clinical guidelines, ... deadline really critical" Two experts will debate that question ... for Cardiovascular Angiography and Interventions (SCAI). ,Allowing ...
... artificial plastic blood, which they claim could act as a ... in war zones. ,The new artificial blood ... atom at their core, like haemoglobin, that can carry oxygen ... looking for extra funding to develop a final prototype that ...
... an outbreak of mumps beginning in Nova Scotia and now ... are the most affected. ,The latest outbreak of ... in Nova Scotia has put health officials in top alert. ... to administer a booster shot, as the latest attacks prove ...
... at Chicago explain in the May 11 issue of Circulation ... to slow the rapid beating of the heart's "fight-or-flight" reaction ... right chamber is responsible for setting the pace of the ... human heart, one cell - the pacemaker cell - beats ...
Cached Medicine News:Health News:China Eyeing US Cooked Chickens Market 2Health News:Blind Faith Dictates Use Of Herbal Supplements In Many 2Health News:Debate Focuses on Door-to-balloon Time in Heart Attack Treatment 2Health News:Mumps Breaks Out In Canada 2Health News:Slowing the Racing Heart 2
(Date:8/30/2015)... 31, 2015 Noser Health ... to deliver new platform ... citizen-owned health data transaction platform, announced today strategic partnerships ... to engineer and bring to market its global health ... "Our business model is built on trust, ...
(Date:8/28/2015)... 2015  Delays in the launch and execution ... the decision-making process, resulting in missed opportunities and ... biopharmaceutical companies to develop a tactical approach to ... and more meaningful insights. According ... three-quarters of benchmarked study participants use review cycle ...
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Bevacizumab ... Developed by Roche under the trade name of Avastin, ... world. In Feb.26, 2010, it was approved by CFDA ... in China all come from ...
Breaking Medicine Technology:healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 2healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 3healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 4Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Bevacizumab Market 2015-2019 2
... Technologies, Inc. (the "Company") (Nasdaq: CMED ), ... announced that it has made the payment for all ... 3.5% Convertible Senior Subordinated Notes (the "2011 Notes") which ... 2011 Notes will be cancelled accordingly. None of the ...
... Scripts, Inc. (Nasdaq: ESRX ) announced today ... Delaware corporation (“Aristotle”), has successfully priced a private offering ... amount of 2.750% senior notes due 2014, $1.25 billion ... $1.25 billion aggregate principal amount of 4.750% senior notes ...
Cached Medicine Technology:Express Scripts, Inc. Announces Pricing of $4.1 Billion Senior Notes Offering 2Express Scripts, Inc. Announces Pricing of $4.1 Billion Senior Notes Offering 3Express Scripts, Inc. Announces Pricing of $4.1 Billion Senior Notes Offering 4Express Scripts, Inc. Announces Pricing of $4.1 Billion Senior Notes Offering 5Express Scripts, Inc. Announces Pricing of $4.1 Billion Senior Notes Offering 6
... were designed for ease of use, and ... blood sample is collected. The wider-diameter BD ... an integrated collection scoop and improved mixing ... is available for hematology and chemistry applications, ...
... The Identity pacemaker family, which includes ... clinicians with the most advanced pacemaker ... Suppression algorithm, the first and only ... suppress atrial fibrillation (AF). The AF ...
... The Identity pacemaker family, which includes ... clinicians with the most advanced pacemaker ... Suppression algorithm, the first and only ... suppress atrial fibrillation (AF). The AF ...
... Identity pacemaker family, which includes the ... with the most advanced pacemaker technology ... algorithm, the first and only U.S. ... atrial fibrillation (AF). The AF Suppression ...
Medicine Products: